A detailed history of Cibc Asset Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cibc Asset Management Inc holds 439,370 shares of GILD stock, worth $40.1 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
439,370
Previous 416,746 5.43%
Holding current value
$40.1 Million
Previous $28.6 Million 28.8%
% of portfolio
0.13%
Previous 0.11%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$66.59 - $83.99 $1.51 Million - $1.9 Million
22,624 Added 5.43%
439,370 $36.8 Million
Q2 2024

Aug 01, 2024

BUY
$63.15 - $72.88 $180,609 - $208,436
2,860 Added 0.69%
416,746 $28.6 Million
Q1 2024

May 09, 2024

SELL
$71.58 - $87.29 $2.12 Million - $2.58 Million
-29,573 Reduced 6.67%
413,886 $30.3 Million
Q4 2023

Feb 13, 2024

SELL
$73.27 - $83.09 $229,847 - $260,653
-3,137 Reduced 0.7%
443,459 $35.9 Million
Q3 2023

Oct 30, 2023

BUY
$73.94 - $80.67 $2.28 Million - $2.49 Million
30,871 Added 7.43%
446,596 $33.5 Million
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $1.06 Million - $1.21 Million
-13,985 Reduced 3.25%
415,725 $32 Million
Q1 2023

May 12, 2023

SELL
$77.31 - $88.08 $1.73 Million - $1.97 Million
-22,373 Reduced 4.95%
429,710 $35.7 Million
Q4 2022

Feb 13, 2023

SELL
$62.32 - $89.47 $4.34 Million - $6.23 Million
-69,662 Reduced 13.35%
452,083 $38.8 Million
Q3 2022

Nov 03, 2022

BUY
$59.54 - $68.01 $271,442 - $310,057
4,559 Added 0.88%
521,745 $32.2 Million
Q2 2022

Aug 09, 2022

SELL
$57.72 - $65.01 $271,630 - $305,937
-4,706 Reduced 0.9%
517,186 $32 Million
Q1 2022

May 06, 2022

BUY
$57.92 - $72.58 $2.78 Million - $3.48 Million
47,938 Added 10.11%
521,892 $31 Million
Q4 2021

Feb 08, 2022

BUY
$64.88 - $73.64 $1.3 Million - $1.48 Million
20,113 Added 4.43%
473,954 $34.4 Million
Q3 2021

Nov 09, 2021

BUY
$67.69 - $73.03 $9.99 Million - $10.8 Million
147,614 Added 48.2%
453,841 $31.7 Million
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $290,819 - $317,761
4,582 Added 1.52%
306,227 $21.1 Million
Q1 2021

May 14, 2021

SELL
$60.0 - $68.46 $160,020 - $182,582
-2,667 Reduced 0.88%
301,645 $19.5 Million
Q4 2020

Feb 03, 2021

BUY
$56.65 - $64.55 $903,624 - $1.03 Million
15,951 Added 5.53%
304,312 $17.7 Million
Q3 2020

Nov 05, 2020

BUY
$62.1 - $78.08 $4.61 Million - $5.8 Million
74,308 Added 34.71%
288,361 $18.2 Million
Q2 2020

Jul 28, 2020

SELL
$72.34 - $84.0 $3.81 Million - $4.43 Million
-52,708 Reduced 19.76%
214,053 $16.5 Million
Q1 2020

Apr 30, 2020

SELL
$62.63 - $80.22 $17.7 Million - $22.7 Million
-283,255 Reduced 51.5%
266,761 $19.9 Million
Q4 2019

Feb 14, 2020

BUY
$61.62 - $67.78 $2.8 Million - $3.08 Million
45,382 Added 8.99%
550,016 $35.7 Million
Q3 2019

Oct 30, 2019

BUY
$62.51 - $69.0 $10.4 Million - $11.5 Million
165,965 Added 49.01%
504,634 $32 Million
Q2 2019

Aug 05, 2019

BUY
$61.87 - $69.38 $604,964 - $678,397
9,778 Added 2.97%
338,669 $22.9 Million
Q1 2019

May 06, 2019

BUY
$62.53 - $70.05 $760,177 - $851,597
12,157 Added 3.84%
328,891 $21.4 Million
Q4 2018

Feb 12, 2019

BUY
$60.54 - $79.0 $768,736 - $1 Million
12,698 Added 4.18%
316,734 $19.8 Million
Q3 2018

Nov 02, 2018

SELL
$71.28 - $78.92 $2.13 Million - $2.36 Million
-29,872 Reduced 8.95%
304,036 $23.5 Million
Q2 2018

Aug 09, 2018

BUY
$64.88 - $75.68 $10.9 Million - $12.7 Million
168,382 Added 101.73%
333,908 $23.7 Million
Q1 2018

Apr 30, 2018

SELL
$72.84 - $88.8 $99,717 - $121,567
-1,369 Reduced 0.82%
165,526 $12.5 Million
Q4 2017

Feb 02, 2018

BUY
$71.15 - $83.52 $390,969 - $458,942
5,495 Added 3.4%
166,895 $12 Million
Q3 2017

Nov 06, 2017

BUY
$72.11 - $85.47 $11.6 Million - $13.8 Million
161,400
161,400 $13.1 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Cibc Asset Management Inc Portfolio

Follow Cibc Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.